Dermapharm Holding SE (DMP) — Cash Flow-to-Debt Ratio
Dermapharm Holding SE (DMP) has a Cash Flow-to-Debt Ratio of 0.06x as of December 2025, meaning its operating cash flow of €92.40 Million could theoretically repay 0% of its total liabilities (€1.50 Billion) in one year. See Dermapharm Holding SE free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Dermapharm Holding SE Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Dermapharm Holding SE across 12 annual periods. Also explore Dermapharm Holding SE net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Dermapharm Holding SE (2014–2025)
Year-by-year debt coverage analysis for Dermapharm Holding SE. For market capitalisation and broader financial context, see DMP market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | €181.51 Million | €1.50 Billion | ▼ -11.7% |
| 2024 | 0.14x | €201.38 Million | €1.47 Billion | ▲ +0.8% |
| 2023 | 0.14x | €219.42 Million | €1.62 Billion | ▼ -58.6% |
| 2022 | 0.33x | €288.53 Million | €880.34 Million | ▲ +18.8% |
| 2021 | 0.28x | €250.37 Million | €907.13 Million | ▲ +89.4% |
| 2020 | 0.15x | €131.10 Million | €899.81 Million | ▲ +10.1% |
| 2019 | 0.13x | €100.61 Million | €760.38 Million | ▼ -62.7% |
| 2018 | 0.35x | €159.13 Million | €448.50 Million | ▲ +39.7% |
| 2017 | 0.25x | €86.74 Million | €341.62 Million | ▼ -17.0% |
| 2016 | 0.31x | €76.78 Million | €250.89 Million | ▲ +91.2% |
| 2015 | 0.16x | €40.38 Million | €252.22 Million | ▼ -12.5% |
| 2014 | 0.18x | €54.26 Million | €296.59 Million | — |